The research team scrutinized Medicare claims data spanning over a decade, encompassing more than 87,000 patients diagnosed with preexisting atrial fibrillation who underwent isolated CABG between 2008 and 2019. Within this expansive cohort, only about 22% received concurrent surgical ablation—a procedure designed to restore normal heart rhythm by interrupting aberrant electrical pathways within the atria. Although there was a modest increase in adoption rates over time, the procedure was still performed in merely 27% of cases by 2019, two years following a Class I recommendation endorsing ablation by The Society of Thoracic Surgeons.

This low utilization is particularly striking given the study’s key findings: patients receiving surgical ablation experienced a statistically significant increase in median survival by approximately 4.4 months compared to those who did not undergo the procedure. Specifically, survival extended from 7.46 years to 7.82 years, a meaningful difference in the context of this complex cardiovascular population. Beyond patient-level analysis, the study delved into surgeon-level variations, revealing that those treated by surgeons who regularly perform ablations had nearly five additional months of survival compared to those treated by surgeons who seldom implement ablation techniques.

Dr. Justin Schaffer, the study’s lead author and medical director of surgical outcomes at Baylor Scott & White – The Heart Hospital, emphasized that the beneficial effects of surgical ablation manifest primarily in the longer term, becoming apparent more than two years post-CABG. This delayed survival advantage aligns with the hypothesis that surgical ablation reduces the incidence of tachycardia-induced heart failure, a known contributor to morbidity and mortality in patients with atrial fibrillation.

Recognizing that patients selected for ablation might inherently possess better health characteristics, the researchers employed sophisticated statistical methodologies to mitigate treatment selection bias. They used overlap propensity score weighting, a technique that adjusts for observed confounding variables, ensuring that compared groups are similar in measured baseline characteristics. Complementing this, a surgeon-preference instrumental variable analysis leveraged natural variations in surgical practice, contrasting outcomes for patients whose surgeons frequently ablate with those treated by surgeons who rarely do so. This method approximates randomization by assuming patients are quasi-randomly distributed relative to the surgeon’s practice patterns, thereby accounting for unmeasured confounding factors.

The dual analytical approach adds robustness to the conclusions, offering a more comprehensive assessment of surgical ablation’s impact. While randomized controlled trials are the gold standard in clinical research, such a large-scale trial remains unlikely in this domain. Therefore, the consistency of findings across both observational and instrumental variable analyses lends compelling evidence supporting surgical ablation.

Atrial fibrillation complicates the perioperative course in a significant subset of CABG patients, with estimates that 10-20% exhibit this arrhythmia before surgery. This condition is notorious for increasing the risk of surgical complications and diminishing long-term survival. Surgical ablation aims to reestablish sinus rhythm, reducing arrhythmia burden and its deleterious sequelae. Previous smaller studies suggested such benefits, yet widespread adoption has lagged, potentially due to concerns about increased surgical complexity and procedural risk.

The new data underscore the clinical imperative for adherence to guideline-directed therapy, which categorizes surgical ablation during CABG as a Class I recommendation, indicating strong evidence or general agreement about its effectiveness. The persistent underuse, despite clear survival advantages, suggests that surgeon preference, institutional protocols, and possibly logistical barriers influence practice patterns. This highlights an urgent need for educational initiatives and systemic changes to bridge the gap between evidence and implementation.

Moreover, the study’s findings have broader implications in healthcare policy and quality improvement. As value-based care models gain traction, interventions that prolong life and improve outcomes without significant added risk should be prioritized. Surgical ablation, by enhancing survival in a high-risk population already undergoing major surgery, exemplifies such an intervention. Its broader adoption may improve overall cardiovascular health outcomes and reduce long-term healthcare costs associated with managing complications of untreated atrial fibrillation.

Dr. John Squiers, coauthor of the study and cardiothoracic specialist at Baylor Scott & White The Heart Hospital, emphasized the importance of these results in shaping future surgical practice. He expressed hope that this research would prompt reevaluation and refinement of surgical decision-making algorithms, ultimately ensuring that more patients receive this beneficial adjunct therapy.

The full study, entitled “Association of Surgical Ablation During Coronary Artery Bypass Grafting with Survival in Patients with Preexisting Atrial Fibrillation,” provides an in-depth examination of clinical outcomes and statistical methodologies, and is available online through The Annals of Thoracic Surgery. With this groundbreaking evidence, the medical community is called to action to integrate surgical ablation more consistently into care pathways for patients with atrial fibrillation undergoing CABG.

This research not only delineates the survival advantage but also challenges the status quo, urging surgeons, institutions, and policymakers to reconsider current practices. By addressing the underutilization of surgical ablation, there exists a tangible opportunity to improve the prognosis of tens of thousands of patients annually. Future studies may focus on identifying and overcoming barriers to adoption, optimizing perioperative protocols, and exploring combined strategies that integrate ablation with novel pharmacologic and device therapies.

In a landscape where cardiovascular disease remains the leading cause of morbidity and mortality globally, the findings from this extensive Medicare cohort study resonate profoundly. They provide the evidence base needed to advance care and underscore the vital role of evidence-aligned surgical interventions in improving long-term patient survival.

Subject of Research: Survival outcomes associated with surgical ablation of atrial fibrillation during coronary artery bypass grafting in Medicare patients.

Article Title: Survival After Surgical Ablation of Atrial Fibrillation During Coronary Artery Bypass in Medicare Beneficiaries

News Publication Date: June 3, 2025

Web References:
https://www.annalsthoracicsurgery.org/article/S0003-4975(25)00339-X/fulltext

References: DOI 10.1016/j.athoracsur.2025.03.044

Coronary artery bypass grafting is a lifesaving procedure designed to restore adequate blood supply to heart muscles compromised by atherosclerotic blockages. Traditionally, the saphenous vein from the leg is harvested and grafted onto coronary arteries downstream of occlusions to reroute blood flow. However, the conventional harvesting process involves stripping the vein of its surrounding connective tissue, a step now proven to contribute to higher rates of graft occlusion—where the graft becomes narrowed or blocked, jeopardizing the bypass’s effectiveness.

The no-touch harvesting technique represents a paradigm shift. Rather than isolating the vein alone, this method removes the vein encased in a protective cushion of surrounding perivascular tissue. This approach reduces mechanical trauma and preserves the vascular endothelial function vital for keeping the graft patent. Data from the initial PATENCY trial already demonstrated significantly improved graft patency rates at 3 and 12 months post-surgery. Yet, the lingering question concerned the durability of these benefits over the longer term.

To address this crucial gap, Chinese researchers conducted a meticulously designed multicenter randomized controlled trial involving 2,655 patients undergoing CABG. Participants were randomly assigned to either the no-touch or conventional vein harvesting groups and followed for three years. This robust sample included both genders and a range of ages, providing a realistic overview of clinical outcomes across diverse patient demographics. The study’s methodological rigor lends strong credibility to its findings, which have far-reaching implications for cardiac surgery worldwide.

At the three-year mark, the results were compelling. Patients treated with the no-touch technique exhibited a vein graft occlusion rate of just 5.7%, compared with 9% in the conventional group. This marked reduction in occlusion underscores the mechanistic advantages of the no-touch approach, including preservation of vein elasticity, reduced endothelial injury, and minimized inflammatory response. By maintaining vein integrity, the no-touch method directly addresses one of the most critical failure modes in CABG surgery.

But the benefits were not limited to graft patency alone. Clinical endpoints related to heart health also favored the no-touch group. The incidence of non-fatal myocardial infarctions was less than half that seen in patients with conventional vein harvesting (1.2% vs. 2.7%). Similarly, rates of repeat revascularisation—a procedure performed to restore blood flow when initial grafts fail—were significantly lower (1.1% compared to 2.2%). These outcomes translate into fewer heart attacks, reduced need for additional procedures, and ultimately better long-term survival and quality of life for patients.

Recurrent angina and cardiac-related hospital readmissions also decreased in the no-touch cohort. Specifically, recurrent angina was reported in 6.2% of no-touch patients versus 8.4% among those with conventional harvesting, while cardiac-related readmissions occurred in 7.1% vs. 10.2%, respectively. These reductions indicate enhanced graft function and fewer complications, which not only benefit patient welfare but also reduce healthcare costs and burdens on medical infrastructure.

Interestingly, the study found no statistically significant differences between groups in all-cause mortality and the composite measure of major adverse cardiac and cerebrovascular events. This suggests that while the no-touch technique markedly improves graft patency and related morbidity, the ultimate impact on death rates requires further long-term investigation, perhaps beyond the three-year follow-up window of this study. Continued monitoring may clarify these trends and affirm the extended benefits of this surgical innovation.

Researchers acknowledge several limitations intrinsic to the trial. The cohort was predominantly composed of relatively young Chinese patients, which may limit applicability to older populations or different ethnic groups. Additionally, while the trial’s design minimized bias, some findings could reflect random variation rather than definitive biological effects. Nonetheless, secondary analyses supported the robustness of the results, and no substantial confounding factors were identified that would undermine the core conclusions.

From a mechanistic perspective, the preservation of the perivascular tissue appears crucial. The surrounding connective tissue provides mechanical support and contains vasa vasorum—small blood vessels that nourish the vein wall. By maintaining this structure intact, the no-touch technique guards against vein spasm and endothelial denudation, processes known to accelerate graft failure. This protective "cushion" acts almost like a natural graft dressing, fostering better biological integration and endothelial healing.

The implications of these findings extend beyond the clinical trial itself. Cardiac surgeons and guideline committees worldwide may need to reconsider current harvesting protocols in favor of the no-touch method. Given the simplicity and cost-effectiveness of adapting to this technique—primarily involving modified surgical tools and training—its widespread adoption could meaningfully improve CABG outcomes globally. Such a shift promises to reduce repeat surgeries, lower healthcare expenditures, and enhance patient quality of life.

Notably, Hui Jiang, professor of cardiac surgery at Shengjing Hospital of China Medical University, underscores this point in an accompanying editorial. Despite acknowledging trial limitations and the need for further monitoring, he hails the no-touch technique as a critical advance that could reshape surgical strategies and guideline formulations. This endorsement from a leading cardiac expert adds weight to the growing momentum behind this novel approach.

In conclusion, the three-year follow-up of the PATENCY trial delivers robust evidence affirming that the no-touch vein harvesting technique significantly reduces vein graft occlusion and associated cardiac complications after CABG surgery. By preserving the vein’s surrounding tissue, this method not only protects graft integrity but translates into tangible clinical benefits, lowering the risk of heart attacks, repeat interventions, and hospitalizations. As CABG remains a cornerstone treatment for coronary artery disease, these findings may herald a new standard of care, improving outcomes for millions of patients worldwide.

The study’s detailed results and supporting analyses, now available in The BMJ, will undoubtedly stimulate further research and debate, encouraging cardiac surgical teams to evaluate and potentially adopt the no-touch harvesting technique. Continued follow-up beyond three years will be essential to elucidate long-term survival impacts and consolidate these promising findings. For now, this veterinary trial marks a significant step forward in cardiovascular surgery, offering renewed hope for enhanced graft durability and better lives for heart disease patients.

Subject of Research: People

Article Title: No-touch versus conventional vein in coronary artery bypass grafting: three year follow-up of multicentre randomised PATENCY trial

News Publication Date: 30-Apr-2025

Web References: http://dx.doi.org/10.1136/bmj-2024-082883

Keywords: Surgical procedures, Coronary artery bypass grafting, No-touch vein harvesting, Vein graft occlusion, Cardiac surgery, Randomized controlled trial